Patient-Level Data for Drugs and Biological Products Submissions Containing Real-World Data and Real-World Evidence; Request for Information
By Human Services Department, Food, Health, Drug Administration · Nov 11, 2026, 11:00 PM CST
The Food and Drug Administration (FDA or Agency), is announcing a request for information (RFI) from interested parties to share perspectives on patient-level data access related to the use of real-world evidence (RWE) in regulatory decision-making for drugs and biological product submissions. The purpose of this RFI is to solicit input from interested parties on innovative solutions to address th
Excerpt shown under fair-use limits. Full text remains with the original publisher.
People in this coverage
Explore their history and attributable record. Being mentioned does not imply endorsement.
Layer 1 · Claims & fact checks
AI analysisLayer 3 · Reporting analysis
AI analysisFramingThe announcement frames the RFI as a collaborative effort to solve challenges, positioning the FDA as seeking external expertise.
Audience TargetingThe list explicitly names a broad set of stakeholders, indicating an inclusive outreach strategy.
Context
AI analysisMissing context
The announcement does not explain the specific regulatory challenges that have prompted the RFI, nor does it detail how the FDA intends to use the information gathered, any timelines for response, or potential impacts on existing submission processes.
Important context
Real‑world evidence is increasingly used by regulators to complement clinical trial data, and patient‑level data raises privacy, data‑standardization, and feasibility concerns that the FDA is seeking to address through stakeholder input.
Opinion vs. reporting
AI analysisThe text is purely informational; it reports the FDA's RFI without editorializing or presenting opinion.